Literature DB >> 18453785

[Development of acute coronary syndrome in three patients with essential thrombocythemia or polycythemia vera].

Meltem Tekin1, Serkan Gökaslan, Erdem Diker, Sinan Aydoğdu.   

Abstract

Little is known about the management of coronary thrombosis in myeloproliferative disease. The occurrence of myocardial infarction in myeloproliferative disease is mostly attributed to coronary thrombosis due to hyperviscosity and thrombocytosis. We presented three cases of acute myocardial infarction associated with polycythemia vera in one patient (male, age 33 years) and essential thrombocytosis in two patients (male, ages 36 and 46 years). None of the patients had diabetes mellitus, hypertension, hyperlipidemia, or a positive family history. One patient with early presentation received thrombolytic therapy, and all the patients were treated with aspirin, beta-blocker, angiotensin 2 receptor blocker, statin, low-molecular-weight heparin, parenteral nitrate, and clopidogrel for acute coronary syndrome, and hydroxyurea for essential thrombocytosis. Control angiographies showed patent coronary arteries in all the cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18453785

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  3 in total

1.  Polycythemia vera presenting as acute myocardial infarction: An unusual presentation.

Authors:  Hussain Bahbahani; Khaled Aljenaee; Abdelhaleem Bella
Journal:  J Saudi Heart Assoc       Date:  2014-07-28

2.  Acute Myocardial Infarction as First Onset of Polycythemia Vera.

Authors:  Caroline Ferreira da Silva Mazeto Pupo da Silveira; Lívia Beatriz Santos Limonta Vitali; Fabiana Garcia Faustino; Alejandra Del Carmen Villanueva Maurício; Renato Teixeira; Silméia Garcia Zanati Bazan
Journal:  Arq Bras Cardiol       Date:  2020-05-18       Impact factor: 2.000

3.  Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.

Authors:  Bassel Nazha; Gwenalyn Garcia; Ruben Kandov; Marcel Odaimi
Journal:  Case Rep Hematol       Date:  2015-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.